Company intelligence / Profile preview

Centafore

Ownership: Private
Development stage: Commercial

Overview

Centafore is an imaging core lab service launched by Bayer in 2025 to provide comprehensive image management, processing, interpretation, and expert project management for clinical trials and SaMD development. It leverages over 25 years of internal experience supporting more than 200 clinical trials. The service aims to improve trial reliability with advanced analysis tools and board-certified radiologists operating in over 50 countries. It is currently collaborating with organizations such as OBIO and Luxsonic Technologies.

Therapeutic areas: OncologyOtherDermatologyCardiovascularNeurologyWomen's Health
Modalities: Medical imagingSoftware as a Medical Device (SaMD)Digital health solutions
Industry: Contract Research Organization

Partnerships

OBIO (Ontario Bioscience Innovation Organization)Luxsonic Technologies

Beyond the preview

Go deeper on Centafore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Centafore.

Explore the full profile